Year: 2015
Type: article
Abstract: Despite significant investments in the development of new agents only 5% of cancer drugs entering Phase I clinical trials are ultimately approved for routine clinical cancer care. Drug repurposing strategies using novel combinations of previously tested anticancer agents could reduce the cost and improve treatment outcomes. At MD Anderson Cancer Center, early phase clinical trials with drug repurposing strategies demonstrated promising outcomes in patients with both rare and common treatment refractory advanced cancers. Despite clinical efficacy advancing drug repurposing strategies in the clinical trial trajectory beyond early phase studies has been challenging mainly due to lack of funding and interest from the pharmaceutical industry. In this review, we delineate our experience and challenges with drug repurposing strategies.
Source: Oncoscience
Language: English
Subfield: Statistics and Probability
Field: Mathematics
Domain: Physical Sciences
Open Access status: diamond
Funders: National Institutes of Health, University of Texas MD Anderson Cancer Center, Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, National Cancer Institute, National Center for Advancing Translational Sciences, Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy
OpenAlex ID: W2465131028